ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients

Yufeng Song[1], Regan Myers[1], Lila Murphy[1,2], Bailey Brooks[1,2], Jeffrey M. Wilson[3], Alexandra Kadl[4,5], Judith Woodfolk[4],Steven L. Zeichner[1,6]*

[1]Department of Pediatrics, University of Virginia

[2]College of Arts and Sciences, University of Virginia

[3]Division of Allergy and Clinical Immunology, Department of Medicine, University of Virginia

[4]Department of Medicine, University of Virginia

[5]Department of Pharmacology, University of Virginia

[6]Department of Microbiology, Immunology, and Cancer Biology, University of Virginia

*Correspondence: zeichner@virginia.edu

Abstract

Many mechanisms responsible for COVID-19 pathogenesis are well-established, but COVID-19 includes features with unclear pathogenesis, such as autonomic dysregulation, coagulopathies, and high levels of inflammation. The receptor for SARS-CoV-2 spike protein's receptor binding domain (RBD) is angiotensin converting enzyme 2 (ACE2). We hypothesized that some COVID-19 patients may develop antibodies that have negative molecular image of RBD sufficiently similar to ACE2 to yield ACE2-like catalytic activity – ACE2-like abzymes. To explore this hypothesis, we studied patients hospitalized with COVID-19 who had plasma samples available obtained about 7 days after admission. ACE2 is a metalloprotease that requires Zn^{2+} for activity. However, we found that the plasma from some patients studied could cleave a synthetic ACE2 peptide substrate, even though the plasma samples were collected using disodium ethylenediaminetetraacetate (EDTA) anticoagulant. When we spiked plasma with synthetic ACE2, no ACE2 substrate cleavage activity was observed unless Zn^{2+} was added or the plasma was diluted to decrease EDTA concentration. After processing samples by 100 kDa size exclusion columns and protein A/G adsorption, which depleted immunoglobulin by >99.99%, the plasma samples did not cleave the ACE2 substrate peptide. The data suggest that some patients with COVID-19 develop antibodies with abzyme-like activity capable of cleaving synthetic ACE2 substrate. Since abzymes can exhibit promiscuous substrate specificities compared to the enzyme whose active site image they resemble, and since proteolytic cascades regulate many physiologic processes, anti-RBD abzymes may contribute to some otherwise obscure COVID-19 pathogenesis.

Introduction

The primary pathology in COVID-19 involves pulmonary disease[1-3]. Other end organ involvement, likely directly attributable to infection with the virus, can include gastrointestinal disease, such as diarrhea, and loss of smell and taste[2-4]. While the basic pathophysiology of COVID-19 is well-established, COVID-19 has many baffling features, including disorders involving high inflammation, disorders of the clotting cascade, and problems with blood pressure homeostasis[2, 5, 6]. Some sequelae do not develop until a week or more after infection, suggesting that their pathogenesis may result from secondary processes.

Reports suggest that some of the inflammatory processes associated with COVID-19 may relate to antibodies against the SARS-CoV-2 spike protein, S. For example, small numbers of children who have received COVID-19 vaccines and have had no evidence of infection with SARS-CoV-2, as well as a small number of infants born to mothers with COVID-19[7] have been described as having multi-system inflammatory syndrome of children (MIS-C)[8].

In addition to acute COVID-19, some patients experience Post-Acute Sequelae of SARS CoV-2 infection (PASC, sometimes called “long COVID”), a heterogeneous group of symptoms that continue after acute infection has resolved and can include evidence of a hyperinflammatory state[9], persistent coagulopathies, and neurophysiologic dysregulation, for example aberrant blood pressure regulation. While some clinical features observable at the beginning of the COVID-19 clinical course, such as SARS-CoV-2 viremia, autoantibodies, inflammatory markers, and activation of Epstein-Barr

71 Virus, may be associated with an increased risk of long COVID[10], the detailed
72 pathogenic processes responsible for PASC remain unclear.
73
74 Membrane-bound angiotensin converting enzyme 2 (ACE2) is the main cellular receptor
75 for SARS-CoV-2. Binding of the SARS-CoV-2 spike protein receptor binding domain
76 (RBD) to ACE2 initiates the pathway that leads to infection of a new host cell. ACE2, a
77 Zn^{2+} metalloenzyme, cleaves angiotensin II into angiotensin 1-7, which has vasodilatory
78 activity. Angiotensin converting enzyme (ACE) cleaves angiotensin I to yield angiotensin
79 II, which has vasoconstrictive and hypertensive effects. ACE2 therefore helps to
80 counteract the hypertensive effects of angiotensin II, and so has blood pressure
81 counterregulatory activity compared to ACE. There have been isolated reports and
82 small case series describing persistent hypotension in patients with COVID-19 and
83 patients with PASC without a clearly identified cause[11-13].
84
85 The kallikrein-kinin system is a proteolytic cascade that helps regulate inflammation
86 (reviewed in [14]). There is cross-talk between the coagulation, kallikrein-kinin,
87 complement and renin-angiotensin systems[15]. Some patients with severe COVID-19
88 respiratory disease have been found to have altered regulation of the kallikrein-kinin
89 system in bronchoalveolar lavage fluid[16]. Abnormalities in the kallikrein-kinin system
90 have been proposed as contributing to the pathogenesis of severe COVID-19[17].
91
92 Catalytic antibodies, “abzymes”[18, 19], are antibodies that have catalytic activity. When
93 abzymes were first described, they generated considerable excitement. Investigators
94 hypothesized that it would be possible to produce clinically and biotechnologically useful
95 abzymes.

However, with additional studies, it became clearer that abzyme activity was significantly lower than the activity of more conventional enzymes (*k*cat/*Km* values ~10^2 - 10^4 s^{-1}•M s^{-1} [20] vs. *k*cat/*Km* values of ~10^5 s^{-1}•M s^{-1})[21]. Hence, interest in the biotechnological applications of abzymes waned, but an appreciation of the potential role of abzymes in the pathogenesis of disease, including autoimmune disease, continued. High concentrations of abzymes in the circulation may compensate for the abzymes' lower activity to yield clinically significant effects.

Patients with autoimmune diseases can make abzymes catalyzing, for example, cleavage of vasoactive intestinal peptide (VIP)[22], DNA[23], immunoglobulin components[24], components of the clotting cascade[25-27], and myelin basic protein (MBP) in patients with multiple sclerosis[28]. Abzymes that cleave the HIV envelope protein have been observed to occur in patients with HIV, so there is precedence for the induction of a catalytic antibody by a virus[29].

Investigators have deliberately made anti-idiotypic abzymes with catalytic activity like the activity of a particular enzyme of interest[30, 31]. Investigators identify an antibody against an enzyme, and then produce an antibody against the anti-enzyme antibody. For some of the anti-idiotypic antibodies, there is enough resemblance to the active site of the enzyme that the anti-idiotypic antibody has catalytic activity resembling the enzyme[32, 33]. In some instances, the substrate specificity of the abzyme differs substantially from that of the original enzyme[31, 32, 34], with the abzyme showing more substrate promiscuity than the original enzyme.

121 The receptor binding domain of the SARS-CoV-2 spike protein uses the ACE2 enzyme
122 on the surface of the target future host cell as its receptor. The RBD is not an antibody,
123 but it does bind ACE2. Taking as an example of abzyme production the anti-idiotypic
124 antibody to an antibody against an enzyme, it is plausible to hypothesize that in some
125 cases, an antibody against the RBD might resemble the ACE2 active site and so have
126 catalytic activity. If an antibody directed against the RBD has some resemblance to
127 ACE2, it is also plausible that anti-RBD antibodies, for some small fraction of patients,
128 might have catalytic activity reminiscent of ACE2. We hypothesized that some COVID-
129 19 patients may develop anti-RBD antibodies, with promiscuous catalytic activity that, in
130 some cases, cleaves substrates in patients to yield clinically significant effects. FIG 1
131 outlines this hypothesis schematically. We therefore undertook a study to explore
132 whether some COVID-19 patients might have antibodies that can cleave an ACE2
133 substrate.
134
135 We studied plasma samples from a group of 67 patients, with samples obtained
136 relatively early in their disease course, on about the 7th day of hospitalization. We
137 tested plasma using an established fluorometric assay for ACE2 activity, which detects
138 cleavage of an ACE2 peptide substrate. We found that some of the patients had ACE2
139 substrate peptide cleavage activity when the assay was run directly on disodium
140 ethylenediaminetetraacetate (EDTA)-anticoagulated plasma samples, even though
141 ACE2 is a metalloprotease that requires Zn^{2+} for activity. Recombinant ACE2 added to
142 plasma did not show ACE2 substrate-cleaving activity unless $ZnCl_2$ was added to
143 samples at concentrations greater than the EDTA. Processing the samples through a
144 100 KDa size exclusion column followed by absorption with protein A/G beads, which
145 depleted IgG by >99.99%, eliminated the ability of the samples to cleave the ACE2

146 peptide substrate, supporting the hypothesis that a fraction of COVID-19 patients may

147 develop antibodies that have ACE2 substrate cleavage activity.

148

149

150 # Methods

151 ## Clinical Cohort

152 The clinical cohort was recently described in more detail in another publication[35]. The
153 hypothesis motivating that work held that COVID-19 would lead to large scale
154 reactivation of lymphotrophic herpesviruses EBV and HHV-6, but the data obtained in
155 the study did not support that hypothesis. In brief, the University of Virginia (UVA)
156 enrolled a prospective cohort of moderate to severe COVID-19 adult patients admitted
157 to the hospital with a diagnosis confirmed by a nucleic acid amplification test. Patients
158 consented were entered into the study. Clinical data were entered into study databases.
159 Plasma was collected into clinical standard lavender top (EDTA anticoagulant) tubes.
160 Samples were processed in the UVA Biorepository and Tissue Facility and stored at -80
161 C. Study participants (n=67) were adults ages 18 years and above. We used samples
162 obtained on or about day 7 of hospitalization for this study, prior to anti-inflammatory
163 drug administration. The predominant viral strain for our sample was the alpha strain
164 with 98.51% of our sample (66 patients) being collected before July of 2021.The sample
165 collection protocol was approved by the UVA IRB (HSR #200110), and approval was
166 obtained to work on the specimens (HSR #HSR200362), and it follows the
167 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
168 guidelines. EDTA-anticoagulated healthy normal donor plasma was purchased from
169 Valley Biomedical (Cat. #HP1051P), aliquoted and stored in -20℃ according to
170 manufacturer's instructions.

171

172 ## Angiotensin II Converting Enzyme (ACE2)-like Abzyme Activity Detection

173 Abzyme catalytic activities in plasma samples were measured using an Angiotensin II
174 Converting Enzyme (ACE2) Activity Assay Kit, Fluorometric (Abcam, Cat. #ab273297)

175 according to the manufacturer's protocol. This assay employs a synthetic ACE2 peptide
176 substrate labeled with a fluor and a quencher. The manufacturer's product information
177 claims a lower limit of detection for an unmodified assay of 400 μU. The manufacturer
178 does not release detailed information concerning the peptide substrate, holding that
179 information as a trade secret. The kit includes recombinant human ACE2 (ACE2) for
180 use as a positive control. 50μl plasma was added to wells in a 96-well black flat bottom
181 assay plate (Corning, Cat. #3603) and incubated at room temperature (RT), in the dark
182 for 15 min. Then, 50μl of substrate pre-diluted according to manufacturer's protocol was
183 added into the wells of the plate, mixing the substrate with the plasma sample. The
184 plate was immediately placed into a SpectraMax® M5 multi-model microplate reader
185 (Molecular Devices) and the Relative Fluorescent Unit (RFU, Ex/Em = 320/420 nm)
186 values were measured in kinetic mode every 20 min for a total of 16 hours at 37℃.
187 ACE2 inhibitor provided in the assay kit was also used for additional controls.
188
189 **Determination of ACE2 Substrate Peptide Cleavage Activity in Plasma Samples**
190 **With and Without Added $ZnCl_2$ or Plasma Dilution**
191 To evaluate whether native ACE2 shed into blood[36, 37] could contribute to the catalytic
192 activity observed in the patient plasma samples, we investigated whether EDTA present
193 in the plasma samples inhibited activity of recombinant ACE2 spiked into the samples.
194 EDTA can inhibit the catalytic activity of ACE2, a Zn^{2+} metaloprotease[38, 39].
195
196 We conducted serial 10-fold dilutions of the normal donor plasma in ACE2 assay buffer
197 from the assay kit and then added and then added 2 μL recombinant positive control
198 ACE2, provided as a positive control in the ACE2 assay kit (Abcam, Cat. #ab273297) to
199 each well to the samples to the samples according to the manufacturer's protocol,

200 conducting the ACE2 assays on the serially diluted samples with the added
201 recombinant ACE2. We also added $ZnCl_2$ to some samples to achieve final
202 concentrations ranging from 0 to 2 mM. Samples containing plasma, recombinant ACE2
203 and $ZnCl_2$ mixture with pre-diluted ACE2 inhibitor served as negative comparisons.
204 Then, 50 μL of substrate (pre-diluted according to manufacturer's protocol) was added
205 into the wells. Relative Fluorescent Units were measured, and data was analyzed as
206 described below.
207
208 **Human IgG Depletion and Detection**
209 To deplete immunoglobulin from the samples, patient plasma samples or pooled healthy
210 donor plasma were centrifuged at 12,000 g at 4 ℃ for 15 min and supernatants were
211 passed through 0.45 μm syringe filter (FisherScientific, Cat. #97204) to remove
212 contaminating particulate matter. We then placed 500 μL of the filtered samples into
213 ultrafiltration columns with 100kDa cut-off ultrafiltration membrane (Pierce™ Cat. #
214 88503) and centrifuged the columns at 12,000 × g at 4 ℃ until > 400 μL of filtrate was
215 produced. To further deplete antibodies in the plasma samples, we then incubated the
216 flow-through fractions with 30 μL pre-washed Protein A/G Magnetic Beads (Life
217 Technologies, Cat. # 88803, 10 mg/mL) at room temperature (RT) for 1 hour, followed
218 by magnetic removal of the beads, and repeated the same incubation procedure with
219 another freshly prepared 30 μL magnetic beads. The resulting processed plasma
220 samples were stored at 4℃ for short times (less than 12 hours) or -20 ℃ for longer
221 times. Human IgG was measured using a Human IgG ELISA Kit (Abcam, Cat.
222 #ab100547) according to the manufacturer's protocol. We added 50 μL processed
223 samples, as well as standards to multi-microwell strips and incubated them at room
224 temperature for 2.5 hours. Strips were washed with wash buffer and 50 μL diluted

225 biotin-labeled IgG detection antibody were then added to each well with subsequent
226 HRP-streptavidin incubation after another wash step. Each incubation was performed at
227 room temperature for at least 1 hour. After washing, 100 μL of TMB One-Step Substrate
228 was added to each well and was incubated for 5 to 15 min at room temperature in the
229 dark with gentle shanking. The reaction was stopped by adding 50 μL Stop Solution to
230 each well. OD values were read at 450 nm using an accuSkan FC micro-well plate
231 reader (ThermoFisher). IgG concentrations were calculated based on standard curves
232 generated with the same batch of assay strips.
233
234 **RBD Binding Assays**
235 We measure IgG binding to the S-RBD in serum with a quantitative ImmunoCAP^{TM}-
236 based system, employing a Phadia 250 (Thermo-Fisher/Phadia), as described[40]. In
237 brief, we biotinylated S-RBD (RayBiotech, Peachtree Corners, GA) and conjugated it to
238 streptavidin-coated ImmunoCAP^{TM}s (Thermo-Fisher/Phadia). We subtracted
239 background signal by subtracting the signal due to unconjugated streptavidin
240 ImmunoCAP^{TM}, which was run in parallel with each sample.
241
242 **Data Analysis**
243 Since the RFU values for the assays conducted on the samples reached 80% of
244 maximum at about 240 min, RFU values observed over 240 min generated by an ACE2
245 kit were used to evaluate ACE2 substrate cleavage activity in the plasma samples. For
246 each sample, a value corrected for baseline fluorescence in the sample was obtained
247 by the subtracting the baseline RFU value from the value at each subsequent time and
248 the sum of the baseline-corrected RFU values over 240 min was calculated using Excel.
249 Subsequent statistical analysis and data visualization was done using R (version 4.2.1)

with the Rstudio environment and packages ggplot2, tidyverse, readr, drc, ggpubr, ggh4x, gridExtra, and scales. Raw data and R scripts used in the analysis are provided in Supplementary Data (S1, S2). Samples with the top 20% and a control bottom 10% RFU values over 240 min were identified for antibody depletion and further assays.

256 **Results**

257 To develop assays with enhanced sensitivity for ACE2 substrate cleavage activity, we
258 used a commercially available kit, in which a synthetic peptide ACE2 substrate labeled
259 with a fluor and a quencher is exposed to sample. ACE2 substrate cleavage activity
260 frees the fluor from quenching, followed by fluorometric evaluation over time. We first
261 established the kit's performance characteristics on commercially purchased EDTA-
262 anticoagulated normal human plasma. ACE2 is as Zn^{2+}-requiring metalloenzyme. Since
263 EDTA was used as the anticoagulant, to make Zn^{2+} unavailable to the Zn^{2+}-requiring
264 metalloenzymes of the enzymes involved in the coagulation cascade, we first
265 established whether exogenously added ACE2 could be detected when added to
266 plasma samples under our assay conditions. We found that exogenously added
267 recombinant ACE2 could not be detected, either using commercially obtained pooled
268 plasma or in plasma samples pooled from our patients and obtained from our sample
269 bank, unless Zn^{2+} was added or unless the plasma was diluted (FIG 2). Since no native
270 ACE2 activity should be detectable in the EDTA-anticoagulated plasma, any ACE2
271 substrate cleavage activity observed in the EDTA-anticoagulated plasma should be due
272 to something other than ACE or another Zn^{2+} metalloprotease.
273
274 We performed the ACE2 assay on EDTA-anticoagulated (obtained using clinical
275 standard lavender top tubes) research participant plasma samples obtained at about the
276 7th day of hospitalization for a cohort of 67 COVID-19 patients with moderate to severe
277 disease. Using these samples, without dilution and without added Zn^{2+}, we found that
278 we could detect cleavage of the ACE2 peptide substrate in some of the patients,
279 suggesting that the ACE2 peptide substrate cleavage activity was produced by an agent

280 with co-factor characteristics different from canonical ACE2 (FIG 3). FIG 4 shows a
281 scatter plot of the RFU values for the 67 patients studied.
282
283 To determine whether the ACE2 substrate cleavage activity was associated with the
284 presence of immunoglobulin in the samples, we developed an immunoglobulin depletion
285 protocol that includes an initial 0.45 um filtration step to remove large aggregates,
286 followed by a 100 KDa size exclusion column chromatography step, and a subsequent
287 staphylococcal A/G bead absorption step. To test whether patients with high RFU had
288 ACE2 substrate cleavage activity associated with immunoglobulin, we selected samples
289 from patients who had RFU values in the top 20% RFU values and which still had
290 sufficient plasma samples remaining for the immunoglobulin depletion procedure and
291 subsequent ACE2 assays. This selection yielded samples from 11 patients, 4, 5, 9, 11,
292 13, 15, 27, 43, 44, 47, and 48. We also selected samples from 3 patients (17, 64, 64)
293 who were among the patients having the bottom 10% of ACE2 substrate cleavage
294 activity and for which sufficient sample was available for the immunoglobulin depletion
295 procedure as negative control. We also included a purchased pooled EDTA-
296 anticoagulated plasma sample as an additional control.
297
298 Table 2 show the results of the immunoglobulin depletion protocol applied to the patient
299 plasma samples from these patients. The process depleted IgG by a factor of
300 >>99.99%, leaving IgG in the samples at <2.5 ng/ml for all samples.
301
302 We then re-assayed these samples to determine whether immunoglobulin depletion
303 was associated with elimination of the ACE2 substrate cleavage activity (FIG 5), and
304 found that for the 11 tested patients with ACE2 substrate cleavage activity in this cohort,

305 depletion of the immunoglobulin was accompanied by elimination of ACE2 substrate
306 cleavage activity.
307
308 If our hypothesis is correct and the ability to cleave an ACE2 substrate is related to Abs
309 against the RBD, then we should be able to observe a correlation between ACE2
310 substrate cleavage activity and the amount of Ab directed against the RBD in the
311 patients' samples. We assayed for anti-RBD Ab binding activity using a modification of
312 an ImmunoCAP™ Assay activity using a Phadia 250 instrument and S-RBD (FIG 6). We
313 found that there was a significant correlation between the amount of Ab in the patient
314 plasma samples capable of binding the RBD and the ACE2 substrate cleavage activity,
315 suggesting that the ACE2 cleavage activity was related to the amount of anti-RBD Ab
316 present in the plasma sample.
317
318
319
320

Discussion

Our experiments indicate that a fraction of patients with COVID-19 have an activity in plasma capable of cleaving a substrate for ACE2. The ACE2 substrate cleavage activity has divalent cation requirements different from native ACE2 and collocates with immunoglobulin presence during an immunoglobulin depletion procedure, suggesting that these patients may have antibodies with abzyme activity.

The ACE2 substrate cleavage activity showed a significant correlation with Ab directed against the RBD, further supporting the hypothesis that some anti-RBD Abs have ACE2 substrate cleavage activity, but there was considerable spread in the identification of ACE2 substrate cleavage activity observed for different levels of anti-RBD Ab. However, this spread would be expected if only a small fraction of Abs elicited against the RBD in fact had ACE2 substrate cleavage activity, with the initiation and maturation of Ab responses directed against the RBD resulting, in part, from non-specific processes.

Since abzymes can have a broadened substrate specificity compared to the original enzyme that they mirror, it is possible that abzymes made in response to SARS-COV-2 infection may cleave a range of substrates, including substrates that form components of important regulatory cascades, like clotting, blood pressure regulation, and inflammation processes, which could account for aspects of COVID-19 that cannot be directly attributed to viral infection and cell and tissue destruction.

Our study had several strengths. We studied a moderate number of patients, with samples collected prospectively from acutely hospitalized patients with clearly established COVID-19 relatively early in their disease course, but likely approaching at

346 least 2 weeks following initial infection. The patients almost certainly were not admitted
347 immediately following initial infection and the samples were obtained about a week after
348 admission, providing enough time for the development of an initial antibody response to
349 SARS-CoV-2 infection. We used a standard, widely-employed kit for ACE2 peptide
350 substrate cleavage activity, standard size exclusion columns, protein A/G bead
351 absorption immunoglobulin depletion techniques, and assays for immunoglobulins. The
352 data showing that the ACE2 substrate cleavage activity was present even when there
353 was sufficient EDTA to chelate the Zn^{2+} essential for ACE2 activity suggests that the
354 ACE2 substrate cleavage activity had important characteristics different from native
355 ACE2. The data that the ACE2 substrate cleavage activity was removed from the
356 samples following processing with size exclusion columns and absorption with protein
357 A/G beads suggests that the non- Zn^{2+}-requiring ACE2 substrate cleavage activity co-
358 localizes with immunoglobulin and the data that ACE2 substrate cleavage activity
359 correlated with Ab against the RBD support the hypothesis that the patients with ACE2
360 substrate cleavage activity may have developed abzymes with this activity.
361
362 However, our study has several limitations. We only studied a limited subset of the
363 patients admitted to our hospital, from patients who consented to the sample banking
364 and study and for whom sufficient sample volumes were available. A
365 contemporaneously collected, matched, prospective set of samples from patients
366 without COVID-19 would have been ideal negative controls, but samples from such
367 subjects were not obtained as part of the sample banking effort. We also only
368 conducted the assays on patient samples obtained at a single time, about 7 days after
369 hospitalization, so we have no data from patients who were discharged, transferred, or
370 died prior to day 7 of hospitalization. More importantly, in this study we have no data

371 from patients later in their disease course or following convalescence from the acute
372 disease. Inflammatory, coagulopathic, and physiologic dysregulatory phenomena
373 predominate in the later stages of COVID-19 and at least some aspects of PASC and
374 MIS-C appear to result from immune-mediated phenomena. However, some of these
375 patients are treated with anti-inflammatory agents, including intravenous
376 immunoglobulin, which would make the study of these patients for abzyme-like activity
377 difficult. If abzymes with promiscuous substrate specificities develop in some COVID-19
378 patients, some of the clinical features of those disorders could potentially be attributed
379 to abzymes, but this study is not able to directly address such additional hypotheses,
380 which would require additional work. In addition, since abzymes can show substantial
381 substrate specificity spread, it is possible that additional patients in our cohort had
382 abzymes with substrate specificity sufficiently divergent from angiotensinogen that it
383 was not detectable using our assay. It is also possible that COVID-19 patients develop
384 anti-RBD antibodies with abzyme-like activity, but that these antibodies have no clinical
385 significance. Some fraction of normal individuals may have ACE2-like abzyme activity,
386 but this activity could have been diluted in the purchased pooled normal control plasma.
387 However, if the abzyme activity in such patients was similar to that observed in the
388 individual positive patients in this study, that activity would still be ~15% of the activity of
389 the positive patients, given the prevalence of detectable abzyme activity in our cohort,
390 and so would have been likely detectable.
391
392 Finally, our study is merely associational. It is possible that we depleted some other,
393 non-immunoglobulin component of COVID-19 patient plasma that has the ability to
394 cleave the ACE2 substrate peptide with our 100 kDa size exclusion plus protein A/G
395 treatment procedure. To unequivocally establish that some COVID-19 patients develop

396 anti-SARS-CoV-2 immune responses that include abzymes, it would be necessary to
397 isolate discrete monoclonal antibodies from patients with ACE2 substrate cleavage
398 activity, and then characterize those monoclonal antibodies in detail. Such work lies
399 outside the perimeters of this current study.
400
401 Nevertheless, our study offers potential additional insight into some of the difficult-to-
402 understand clinical features of COVID-19, and if some of the difficult manifestations of
403 COVID-19 are related to the induction of antibodies with abzyme-like activity, that
404 finding may suggest new therapeutic interventions. Some other viruses also have also
405 evolved to use enzymes located on the target host cell surface as their receptors, so it
406 is conceivable that those other viral infections may also elicit clinically problematic anti-
407 viral antibodies. The number of spike protein RBDs presented to the immune system in
408 a natural infection is vastly greater than the number of RBDs presented to the immune
409 system following vaccination, offering many more opportunities for the induction of wide-
410 ranging antibody responses, unlike the antigen exposure resulting from vaccination.
411 While complications following vaccination are very rare and the risk-benefit calculation
412 greatly favors vaccination, some of the adverse side effects of SARS-CoV-2 vaccines
413 might also be attributable to the rare induction of anti-RBD antibodies with catalytic
414 activity.
415
416 **Institutional Review Board Statement:** The sample collection protocol was approved
417 by the UVA IRB (HSR #200110), and approval was obtained to work on the specimens
418 (HSR #HSR200362).
419

Informed Consent Statement: Informed consent was obtained from all participants involved in the study.

Data Availability Statement: Data is presented in the manuscript and the supplements. Raw data can be obtained on request.

Acknowledgments and Funding: The study was supported by internal funding from the University of Virginia, including the Manning Fund for COVID-19 Research at UVA the Ivy Foundation, the Pendleton Laboratory Fund for Pediatric Infectious Disease Research, a College Council Minera Research Grant, the Coulter Foundation, and NIAID, NIH (R01 AI176515) with sample acquisition costs supported by the HHV-6 Foundation. We thank the study participants for graciously agreeing to be research participants, and the research support staff who enrolled the study participants (led by Linda Bailes RN, Allison Raymond RN and Sarah Struchen RN). We also thank the University of Virginia Biorepository and Tissue Research Facility for processing the samples used in the study and for providing specimens (Technical Director, Patcharin Pramoonjago PhD).

Conflicts of Interest: The authors declare no conflict of interest.

Tables and Figures

Table 1. Patient Demographic and Clinical Characteristics (cohort previously described in [35])
(IQR: interquartile range)

Characteristic	**N = 67,** median, (IQR)
Age at Admission	60 (48, 66)
First Weight (kg)	91 (76, 112)
Unknown	1
Height (m)	1.68 (1.60, 1.83)
Unknown	6
Gender	
Female	28 (42%)
Male	39 (58%)
Race	
African American	23 (34%)
Native American	1 (1.5%)
Caucasian	31 (46%)
Other	12 (18%)
Smoking Status	
Current	1 (2.1%)
Former	14 (29%)
Never	24 (50%)
Unknown	9 (19%)
NA	19
Need for ICU	
No	28 (42%)
Yes	39 (58%)
Need for Intubation	
No	41 (61%)
Yes	26 (39%)
Blood Type	
A-	2 (4.8%)
A+	14 (33%)
AB+	1 (2.4%)
B+	3 (7.1%)
O-	1 (2.4%)
O+	21 (50%)
Not determined	25
Highest Temperature	
<38	42 (49%)
101	12 (18%)
>38.5	12 (18%)
>40	1 (1.5%)
Length of Stay (Days)	10 (5, 22)
Time to Death (Days)	
6	1
10-20	2
20-30	3
>30	2 (
Highest D-Dimer	605 (280, 2,074)
Highest CRP	10 (4, 16)
BMI	33 (27, 38)
Need for Vasopressors	
Yes	44 (66%)
Dexamethasone	
Yes	41 (61%)
Prednisone	
Yes	3 (13%)
Methylprednisolone	
Yes	5 (22%)
Tocilzumab	
Yes	4 (6%)
Remdesivir	
Yes	27 (40%)
Creatinine	1.00 (0.80, 1.45)
Hgb	12.4 (10.8, 13.6)
IFNa3	45 (36, 72)
Not determined	45
Highest Ferritin	1277 (7, 7161)
Not determined	5
Highest Troponin	
<0.04	47 (73%)
0.04-0.4	12 (18%)
>0.6	3 (5%)
Not determined	5
Highest Creatinine	1.10 (0.90, 1.80)

518 Table 2. Plasma IgG concentration before and after antibody depletion for selected
519 patients exhibiting ACE2 substrate cleavage activity in FIG 2, then re-assayed for ACE2
520 substrate cleavage activity with results shown in FIG 4.
521

Patient (#)	IgG Concentration		IgG depletion efficiency (%)
	Pre[a] mg/ml	Post[b] ng/ml	
4	14.62	0.67	>99.99%
5	12.50	1.48	>99.99%
9	24.40	0.96	>99.99%
11	75.41	0.17	>99.99%
13	26.35	2.46	>99.99%
15	13.27	2.47	>99.99%
27	10.53	2.40	>99.99%
43	29.07	0.87	>99.99%
44	11.17	2.29	>99.99%
47	13.15	1.85	>99.99%
48	12.32	2.06	>99.99%

522
523 a: IgG concentration in plasma before antibody depletion
524 b: IgG concentration in plasma after antibody depletion by ultrafiltration and Protein A/G beads
525
526

527
528 **Figure Legends**
529
530 FIG 1. Schematic diagram illustrating the hypothesis underlying the study. The SARS-
531 COV-2 Spike Protein Receptor Binding Domain (RBD) binds ACE2 on the surface of a
532 potential host cells. The RBD has a partial negative image of ACE2. Some antibodies
533 against the RBD may then have a conformation sufficiently like ACE2 to have
534 proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further
535 suggests that the catalytic activity of some antibodies will have a substrate specificity
536 like ACE2, but because the negative image of RBD present antibodies is imperfect,
537 some antibodies with proteolytic activity will have an altered substrate specificity,
538 potentially affecting multiple proteolytic regulatory cascades.
539
540 FIG 2. Inhibition of exogenously added recombinant ACE2 substrate cleavage activity in
541 undiluted EDTA-anticoagulated pooled plasma samples with and without added $ZnCl_2$.
542 ACE2 is a Zn^{2+} metalloprotease. In this ACE2 spiking experiment, no ACE2 activity was
543 detectable when exogenous ACE2 was added to the plasma, unless Zn^{2+} was also
544 added, or unless the plasma was diluted prior to the addition of the spiked-in ACE2.
545 Adding an ACE2 inhibitor blocked detection of the ACE2 activity in all conditions,
546 indicating that the activity was specific for ACE2. The findings indicate that no native
547 ACE2 activity should be detectable in the EDTA-anticoagulated plasma and so any
548 ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should
549 be due to something other than ACE or another Zn^{2+} metalloprotease.
550
551 FIG 3. Survey of ACE2 substrate cleavage activity in plasma from 67 patients with
552 COVID-19 sampled at about day 7 of hospitalization. The plots present the results of the
553 fluorometric assays for ACE2 substrate cleavage activity run on the 67 patients, plus

554 control samples. Several patients, including the 11 patients we selected for further study
555 (4, 5, 9, 11, 13, 15, 27, 43, 44, 47, 48) because they had among the top 20% of RFU
556 values and had sufficient plasma sample remaining for the immunoglobulin depletion
557 protocol, showed an ability to cleave ACE2 substrate. (HDP: commercially purchased
558 pooled healthy donor plasma; HDP+P.C: HDP with added recombinant human ACE2;
559 HDP+P.C+I: HDP+P.C.+ ACE2; inhibitor; P.P.P alone: pooled plasma from negative
560 samples).
561
562 FIG 4. Scatter plot of the background corrected RFU values for the plasma samples
563 from the 67 patients evaluated in this study. The top 20% of values are plotted in red,
564 the middle 70% are plotted in black, and the bottom 10% are plotted in blue. The top
565 20% and bottom 10% were selected for the ACE2 substrate cleavage activity assays
566 before and after immunoglobulin depletion shown in FIG 5.
567
568 FIG 5. ACE2 substrate cleavage activity in patients before and after immunoglobulin
569 depletion. The figure shows ACE2 substrate cleavage activity for 11 patients (4, 5, 9,
570 11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values and for which
571 we had sufficient plasma for immunoglobulin depletion, before (blue points) and after
572 (red points) immunoglobulin depletion by a 100 KDa size exclusion column followed by
573 protein A/G bead absorption. We also show ACE2 substrate cleavage activity assays
574 before and after immunoglobulin depletion for pooled patient plasma (PPP) negative
575 controls and samples from three arbitrarily selected patients, 17, 64, 65, that had among
576 the bottom 10% of RFU values and had sufficient plasma remaining for the
577 immunoglobulin depletion protocol. The data suggest that for the 11 patients

578 demonstrating ACE2 substrate cleavage activity in this cohort, the ACE2 substrate

579 cleavage activity was depleted in an immunoglobulin-associated manner.

580

581 FIG 6. Correlation of ACE2 substrate cleavage activity (ACE2 Activity) with anti-RBD

582 antibody (Ab Against RBD) in patient plasma. Anti-RBD antibody concentrations in

583 plasma samples were determined using ImmunoCAP^{TM} antibody binding assay.

584

585

FIG 1. FIG 1. Schematic diagram illustrating the hypothesis underlying the study. The SARS-COV-2 Spike Protein Receptor Binding Domain (RBD) binds ACE2 on the surface of a potential host cells. The RBD has a partial negative image of ACE2. Some antibodies against the RBD may then have a conformation sufficiently like ACE2 to have proteolytic activity similar to the proteolytic activity of ACE2. The hypothesis further suggests that the catalytic activity of some antibodies will have a substrate specificity like ACE2, but because the negative image of RBD present antibodies is imperfect, some antibodies with proteolytic activity will have an altered substrate specificity, potentially affecting multiple proteolytic regulatory cascades.



FIG 2. Inhibition of exogenously added recombinant ACE2 substrate cleavage activity in undiluted EDTA-anticoagulated pooled plasma samples with and without added $ZnCl_2$. ACE2 is a Zn^{2+} metalloprotease. In this ACE2 spiking experiment, no ACE2 activity was detectable when exogenous ACE2 was added to the plasma, unless Zn^{2+} was also added, or unless the plasma was diluted prior to the addition of the spiked-in ACE2. Adding an ACE2 inhibitor blocked detection of the ACE2 activity in all conditions, indicating that the activity was specific for ACE2. The findings indicate that no native ACE2 activity should be detectable in the EDTA-anticoagulated plasma and so any ACE2 substrate cleavage activity observed in the EDTA-anticoagulated plasma should be due to something other than ACE or another Zn^{2+} metalloprotease.



FIG 3. Survey of ACE2 substrate cleavage activity in plasma from 67 patients with COVID-19 sampled at about day 7 of hospitalization. The plots present the results of the fluorometric assays for ACE2 substrate cleavage activity run on the 67 patients, plus control samples. We identified plasma from 11 patients (4, 5, 9, 11, 13, 15, 27, 43, 44, 47, 48) that showed an ability to cleave ACE2 substrate. (HDP: commercially purchased pooled healthy donor plasma; HDP+P.C: HDP with added recombinant human ACE2; HDP+P.C+I: HDP+P.C.+ ACE2; inhibitor; P.P.P alone: pooled plasma from negative samples).



FIG 4. Scatter plot of the background corrected RFU values for the plasma samples from the 67 patients evaluated in this study. The top 20% of values are plotted in red, the middle 70% are plotted in black, and the bottom 10% are plotted in blue. The top 20% and bottom 10% were selected for the ACE2 substrate cleavage activity assays before and after immunoglobulin depletion shown in FIG 5.



FIG 5. ACE2 substrate cleavage activity in patients before and after immunoglobulin depletion. The figure shows ACE2 substrate cleavage activity for 11 patients (4, 5, 9, 11, 13, 15, 27, 43, 44, 47, 48) who had among the top 20% of RFU values and for which we had sufficient plasma for immunoglobulin depletion, before (blue points) and after (red points) immunoglobulin depletion by a 100 KDa size exclusion column followed by protein A/G bead absorption. We also show ACE2 substrate cleavage activity assays before and after immunoglobulin depletion for pooled patient plasma (PPP) negative controls and samples from three arbitrarily selected patients, 17, 64, 65, that had among the bottom 10% of RFU values and had sufficient plasma remaining for the immunoglobulin depletion protocol. The data suggest that for the 11 patients demonstrating the highest ACE2 substrate cleavage activity in this cohort, the ACE2 substrate cleavage activity was depleted in an immunoglobulin-associated manner.



648 FIG 6. Correlation of ACE2 substrate cleavage activity (ACE2 Activity) with anti-RBD
649 antibody (Ab Against RBD) in patient plasma. Anti-RBD antibody concentrations in
650 plasma samples were determined using ImmunoCAP™ antibody binding assay.
651
652
653
654



655
656
657
658
659
660

References

1. Bajema KL, Oster AM, McGovern OL, Lindstrom S, Stenger MR, Anderson TC, Isenhour C, Clarke KR, Evans ME, Chu VT, Biggs HM, Kirking HL, Gerber SI, Hall AJ, Fry AM, Oliver SE. Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):166-70. PMC7017962

2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. PMC7159299

3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. Jama. 2020 Apr 7;323(13):1239-42.

4. Chung TW, Sridhar S, Zhang AJ, Chan KH, Li HL, Wong FK, Ng MY, Tsang RK, Lee AC, Fan Z, Ho RS, Luk SY, Kan WK, Lam SH, Wu AK, Leung SM, Chan WM, Ng PY, To KK, Cheng VC, Lung KC, Hung IF, Yuen KY. Olfactory Dysfunction in Coronavirus Disease 2019 Patients: Observational Cohort Study and Systematic Review. Open Forum Infect Dis. 2020 Jun;7(6):ofaa199. PMC7284010

5. Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, Gao Y, Cai L, Wang Z, Yin P, Wang Y, Tang L, Deng J, Mei H, Hu Y. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020 Sep;7(9):e671-e8. PMC7351397

6. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020 Oct;26(10):1636-43. PMC7869028

7. De Rose DU, Pugnaloni F, Calì M, Ronci S, Caoci S, Maddaloni C, Martini L, Santisi A, Dotta A, Auriti C. Multisystem Inflammatory Syndrome in Neonates Born to Mothers with SARS-CoV-2 Infection (MIS-N) and in Neonates and Infants Younger Than 6 Months with Acquired COVID-19 (MIS-C): A Systematic Review. Viruses. 2022;14(4):750.

8. Yousaf AR, Cortese MM, Taylor AW, Broder KR, Oster ME, Wong JM, Guh AY, McCormick DW, Kamidani S, Schlaudecker EP, Edwards KM, Creech CB, Staat MA, Belay ED, Marquez P, Su JR, Salzman MB, Thompson D, Campbell AP. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health. 2022 Feb 22. PMC8864018

9. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. Bmj. 2021 Jul 26;374:n1648.

10. Su Y, Yuan D, Chen, D.G., Ng, R.H., Wang, K., Choi, J., Li, S., Hong, S.,, Zhang R, Xie, J., Kornilov, S.A., Scherler, K., Pavlovitch-Bedzyk, A.J., Dong, S., Lausted, C., Lee, I.,, Fallen S, Dai, C.L., Baloni, P., Smith, B., Duvvuri, V.R., Anderson, K.G., Li, J., Yang, F., Duncombe,, C.J. M, D.J., Rostomily, C., Troisch, P., Zhou, J., Mackay, S., DeGottardi, Q., May, D.H,, Taniguchi R, Gittelman, R.M, Klinger, M., Snyder, T.M, Roper, R., Wojciechowska, G., Murray, K.,, Edmark R, Evans, S., Jones, L., Zhou, Y., Rowen, L., Liu, R., Chour, W., Algren, H.A, Berrington,, W.R. W, J.A., Cochran, R.A., Micikas, M.E., the ISB-Swedish COVID19 Biobanking Unit, Terri Wrin, Petropoulos, C.J., Cole, H.R., Fischer, T.D., Wei, W., Hoon, D.S.B., Price, N.D., Subramanian, N.,, Hill JA, Hadlock, J., Magis, A.T., Ribas, A., Lanier, L.L., Boyd, S.D., Bluestone, J.A., Chu, H., Hood,, L. G, R., Greenberg, P.D., Davis, M.M., Goldman, J.D., Heath, J.R.,. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell. 2022.

11. Hanidziar D, Bittner EA. Hypotension, Systemic Inflammatory Response Syndrome, and COVID-19: A Clinical Conundrum. Anesth Analg. 2020 Sep;131(3):e175-e6. PMC7302068

12. Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, Lim PB. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med (Lond). 2021 Jan;21(1):e63-e7. PMC7850225

13. Koudelka M, Sovová E. COVID-19 Causing Hypotension in Frail Geriatric Hypertensive Patients? Medicina (Kaunas). 2021 Jun 18;57(6). PMC8235779

14. Hillmeister P, Persson PB. The Kallikrein–Kinin system. Acta Physiologica. 2012;206(4):215-9.

15. Bekassy Z, Lopatko Fagerström I, Bader M, Karpman D. Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. Nat Rev Immunol. 2022 Jul;22(7):411-28. PMC8579187

16. Martens CP, Van Mol P, Wauters J, Wauters E, Gangnus T, Noppen B, Callewaert H, Feyen JHM, Liesenborghs L, Heylen E, Jansen S, Pereira LCV, Kraisin S, Guler I, Engelen MM, Ockerman A, Van Herck A, Vos R, Vandenbriele C, Meersseman P, Hermans G, Wilmer A, Martinod K, Burckhardt BB, Vanhove M, Jacquemin M, Verhamme P, Neyts J, Vanassche T. Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fluid of patients with severe COVID-19. eBioMedicine. 2022 2022/09/01/;83:104195.

17. Carvalho PRd, Sirois P, Fernandes PD. The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. Peptides. 2021 2021/01/01/;135:170428.

18. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science. 1986 Dec 19;234(4783):1566-70.

19. Pollack SJ, Jacobs JW, Schultz PG. Selective chemical catalysis by an antibody. Science. 1986 Dec 19;234(4783):1570-3.

20. Hilvert D. Critical analysis of antibody catalysis. Annu Rev Biochem. 2000;69:751-93.

21. Bar-Even A, Noor E, Savir Y, Liebermeister W, Davidi D, Tawfik DS, Milo R. The moderately efficient enzyme: evolutionary and physicochemical trends shaping enzyme parameters. Biochemistry. 2011 May 31;50(21):4402-10.

22. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 1989 Jun 9;244(4909):1158-62.

23. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov AG. DNA hydrolyzing autoantibodies. Science. 1992 May 1;256(5057):665-7.

24. Paul S, Li L, Kalaga R, Wilkins-Stevens P, Stevens FJ, Solomon A. Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragment. J Biol Chem. 1995 Jun 23;270(25):15257-61.

25. Thiagarajan P, Dannenbring R, Matsuura K, Tramontano A, Gololobov G, Paul S. Monoclonal antibody light chain with prothrombinase activity. Biochemistry. 2000 May 30;39(21):6459-65.

26. Wootla B, Dasgupta S, Dimitrov JD, Bayry J, Lévesque H, Borg JY, Borel-Derlon A, Rao DN, Friboulet A, Kaveri SV, Lacroix-Desmazes S. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol. 2008 Jun 1;180(11):7714-20.

27. Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N, Pashov A, Sultan Y, Hoebeke J, Kazatchkine MD, Kaveri SV. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med. 1999 Sep;5(9):1044-7.

28. Ponomarenko NA, Durova OM, Vorobiev, II, Belogurov AA, Jr., Kurkova IN, Petrenko AG, Telegin GB, Suchkov SV, Kiselev SL, Lagarkova MA, Govorun VM, Serebryakova MV, Avalle B, Tornatore P, Karavanov A, Morse HC, 3rd, Thomas D, Friboulet A, Gabibov AG. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):281-6. PMC1324791

29. Ponomarenko NA, Vorobiev, II, Alexandrova ES, Reshetnyak AV, Telegin GB, Khaidukov SV, Avalle B, Karavanov A, Morse HC, 3rd, Thomas D, Friboulet A, Gabibov AG. Induction of a protein-targeted catalytic response in autoimmune prone mice: antibody-mediated cleavage of HIV-1 glycoprotein GP120. Biochemistry. 2006 Jan 10;45(1):324-30.

30. Avalle B, Mistro D, Thomas D, Friboulet A. Polyclonal catalytic anti-idiotypic antibodies with a beta-lactamase activity. Ann N Y Acad Sci. 1996 Oct 12;799:172-5.

31. Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Abzyme generation using an anti-idiotypic antibody as the "internal image" of an enzyme active site. Appl Biochem Biotechnol. 1994 May-Jun;47(2-3):229-37; discussion 37-9.

32. Izadyar L, Friboulet A, Remy MH, Roseto A, Thomas D. Monoclonal anti-idiotypic antibodies as functional internal images of enzyme active sites: production of a catalytic antibody with a cholinesterase activity. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8876-80. PMC47463

33. Friboulet A, Izadyar L, Avalle B, Roseto A, Thomas D. Antiidiotypic antibodies as functional internal images of enzyme-active sites. Ann N Y Acad Sci. 1995 Mar 31;750:265-70.

34. Ponomarenko NA, Pillet D, Paon M, Vorobiev, II, Smirnov IV, Adenier H, Avalle B, Kolesnikov AV, Kozyr AV, Thomas D, Gabibov AG, Friboulet A. Anti-idiotypic antibody mimics proteolytic function of parent antigen. Biochemistry. 2007 Dec 18;46(50):14598-609.

35. Brooks B, Tancredi C, Song Y, Mogus AT, Huang M-LW, Zhu H, Phan TL, Zhu H, Kadl A, Woodfolk J. Epstein–Barr Virus and Human Herpesvirus-6 Reactivation in Acute COVID-19 Patients. Viruses. 2022;14(9):1872.

36. García-Escobar A, Vera-Vera S, Jurado-Román A, Jiménez-Valero S, Galeote G, Moreno R. Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19. Biomolecules. 2022 Jan 5;12(1). PMC8774087

37. Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, Liu J, Harville TO. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One. 2021;16(9):e0257016. PMC8415618

38. Tanna A, Guarino L, Tam FWK, Rodriquez-Cubillo B, Levy JB, Cairns TD, Griffith M, Tarzi RM, Caplin B, Salama AD, Cook T, Pusey CD. Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrology Dialysis Transplantation. 2014;30(7):1185-92.

39. Xiao F, Burns KD. Measurement of angiotensin converting enzyme 2 activity in biological fluid (ACE2). Hypertension: Springer; 2017. p. 101-15.

40. Keshavarz B, Wiencek JR, Workman LJ, Straesser MD, Muehling LM, Canderan G, Drago F, Bonham CA, Sturek JM, Ramani C, McNamara CA, Woodfolk JA, Kadl A, Platts-Mills TAE, Wilson JM. Quantitative Measurement of IgG to Severe Acute Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP. Int Arch Allergy Immunol. 2021;182(5):417-24. PMC8018212